Bicara Therapeutics Inc.

The Company historically has funded its operations from the issuance of common stock in connection with its initial public offering ( IPO ), issuance of common stock in connection with its at-the-market offering program (the ATM Program ), issuance of equity securities in a public offering in February 2026, redeemable convertible preferred stock and through debt financing.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2026 of $ 497.3 million will be sufficient to fund the operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these unaudited condensed consolidated financial statements.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

Bicara would cease to be an emerging growth company if it has more than $1.235 billion in total annual gross revenue, it has more than $700.0 million in market value of its stock held by non-affiliates (and it has been a public company for at least 12 months and has filed one annual report on Form 10-K), or it issues more than $1.0 billion of non-convertible debt securities over a three-year period.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

Any unrealized holding gains or losses on debt securities, including their tax effect, are reported as components of Other comprehensive loss in the condensed consolidated statement of operations and comprehensive loss.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

The Black-Scholes option-pricing model requires the use of judgment to develop input assumptions, some of which are highly subjective, including: (i) the fair value of our common stock on the date of grant; (ii) the expected term of the award; (iii) the expected volatility; (iv) the risk-free interest rate; and (v) expected dividends.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

Expected Dividend: We have not paid and do not anticipate paying any dividends in the near future.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

htm EX-99.1 Document Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Updated data from Phase 1 1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R M HNSCC Data from additional Phase 1 1b expansion cohorts evaluating alternate dose regimens in HPV-negative patients expected by Q1 2026 Strong financial position with approximately $437 million in cash and cash equivalents as of June 30, 2025 expected to fund operations into the first half of 2029 BOSTON, August 12, 2025 Bicara Therapeutics Inc.

SEC original ↗Bicara Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

We also look forward to presenting data from two additional Phase 1 1b expansion cohorts evaluating alternate dose regimens in patients with HPV-negative disease, which are expected to further characterize the safety and efficacy profile of ficerafusp alfa in this population with high unmet need.

SEC original ↗Bicara Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Additional Phase 1b expansion cohorts evaluating ficerafusp alfa in 1L R M HNSCC remain ongoing Data from a cohort evaluating 750mg of ficerafusp alfa weekly in combination with pembrolizumab in HPV-negative patients are expected to be presented at a medical meeting in the fourth quarter of 2025 or the first quarter of 2026.

SEC original ↗Bicara Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Development of Ficerafusp Alfa Across Other Solid Tumor Types A Phase 1b expansion cohort evaluating ficerafusp alfa both as monotherapy and in combination with pembrolizumab in patients with 3L+ metastatic colorectal cancer (RAS B-Rapidly Accelerated Fibrosarcoma (BRAF) wild type) is enrolling.

SEC original ↗Bicara Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Exhibits 92 Signatures 94 SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS We are subject to numerous risks and uncertainties, including those further described below in the section titled Risk Factors in this Quarterly Report on Form 10-Q, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that are difficult to predict.

SEC original ↗Bicara Therapeutics Inc. — Earnings release (8-K exhibit)EX-99Aug 12, 2025

Legal Proceedings 39 Item 1A.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

Exhibits 92 Signatures 94 SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS We are subject to numerous risks and uncertainties, including those further described below in the section titled Risk Factors in this Quarterly Report on Form 10-Q, that represent challenges that we face in connection with the successful implementation of our strategy and the growth of our business.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

In particular, the following considerations, among others, may offset our competitive strengths or have a negative effect on our business strategy, which could materially adversely affect our business, financial conditions, results of operations, future growth prospects, or cause a decline in the price of our common stock: We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

Unfavorable global economic and geopolitical conditions could adversely affect our business, financial condition, stock price and results of operations.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026

Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations and future growth prospects.

SEC original ↗Bicara Therapeutics Inc. — 10-Q Quarterly report10-QAug 11, 2026